Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sterling Capital Management LLC

Sterling Capital Management LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1,584.4% during the 3rd quarter, Holdings Channel reports. The firm owned 93,920 shares of the biopharmaceutical company’s stock after acquiring an additional 88,344 shares during the quarter. Sterling Capital Management LLC’s holdings in Gilead Sciences were worth $13,999,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Client 1ST Advisory Group LLC lifted its stake in shares of Gilead Sciences by 4.0% during the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 69 shares during the period. Davidson Trust Co. increased its position in shares of Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 74 shares during the period. Grove Bank & Trust increased its position in shares of Gilead Sciences by 1.2% in the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after acquiring an additional 74 shares during the period. Financial Connections Group Inc. raised its stake in Gilead Sciences by 30.2% in the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 76 shares during the last quarter. Finally, Wilkerson Advisory Group LLC raised its stake in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the transaction, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at $25,166,417.12. The trade was a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock worth $15,877,860 in the last three months. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $1.15 during mid-day trading on Friday, reaching $156.04. 6,070,692 shares of the stock were exchanged, compared to its average volume of 5,700,578. Gilead Sciences, Inc. has a 1 year low of $114.02 and a 1 year high of $160.51. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a market capitalization of $193.48 billion, a P/E ratio of -58.44 and a beta of 0.31. The business’s 50 day moving average is $149.10 and its 200-day moving average is $137.85.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the previous year, the business earned $2.01 EPS. Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GILD. Zacks Research cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Barclays cut their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 8th. Jefferies Financial Group reaffirmed a “buy” rating and set a $185.00 target price on shares of Gilead Sciences in a report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research report on Thursday, October 8th. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $159.81.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.